Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. Its segments include finished pharmaceutical products and API products. The finished pharmaceutical products segment manufactures, markets and distributes Primatene MIST, epinephrine, glucagon, phytonadione, lidocaine, enoxaparin, naloxone, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes RHI API and porcine insulin API for external customers and internal product development. Its pipeline has over 20 product candidates, including generic ANDAs, biosimilar, and others.
BörsenkürzelAMPH
Name des UnternehmensAmphastar Pharmaceuticals Inc
IPO-datumJun 25, 2014
CEODr. Yongfeng (Jack) Zhang, Ph.D.
Anzahl der mitarbeiter2028
WertpapierartOrdinary Share
GeschäftsjahresendeJun 25
Addresse11570 6th St
StadtRANCHO CUCAMONGA
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl91730
Telefon19099809484
Websitehttps://amphastar.com/
BörsenkürzelAMPH
IPO-datumJun 25, 2014
CEODr. Yongfeng (Jack) Zhang, Ph.D.
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten